Top Stock Gainers Driven by EPS Estimate Revisions: QNRX Up 40.9%, IOT Up 24% - July 2, 2026
On July 2, 2026, stocks that received upward EPS estimate revisions continued to outperform. QNRX surged 40.9% since detection on June 23, with its forward EPS growth estimate raised from 45.4% to 54.8%. IOT, NMAX, HNGE, and MRNA also posted gains between 18.6% and 24.0%, supported by sector momentum and positive earnings outlooks.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| QNRX | Healthcare | 2026-06-23 | +9.5pp | +40.9% |
| IOT | Technology | 2026-06-25 | N/A | +24.0% |
| NMAX | Communication Services | 2026-06-28 | +217.8pp | +20.0% |
| HNGE | Healthcare | 2026-06-24 | N/A | +19.1% |
| MRNA | Healthcare | 2026-06-28 | N/A | +18.6% |
Why did QNRX stock jump in July 2026?
QNRX jumped 40.9% (from $3.25 to $4.58) after analysts raised its forward EPS growth estimate from 45.4% to 54.8% on June 23.
The revision came as part of a broader healthcare sector rally, with small-cap biotech stocks gaining traction. Despite no company-specific news, the significant upward revision signaled improving profitability expectations. The screener detected this shift early, capturing a 40.9% gain in just nine trading days.
QNRX EPS revision history → · Screener snapshot from 2026-06-23 →
FAQ: QNRX
Why did QNRX stock jump in late June 2026?
QNRX surged 40.9% after analysts revised its next-year EPS growth estimate upward from 45.4% to 54.8% on June 23, reflecting improved earnings expectations.
Is QNRX a buy after the rally?
The 40.9% gain followed a +9.5 percentage point EPS revision, but investors should consider the lack of company news and evaluate valuation relative to the revised growth rate.
What is QNRX's EPS growth estimate?
As of the revision on June 23, 2026, QNRX's forward EPS growth estimate stands at 54.8%, up from 45.4%.
Why did IOT stock jump in July 2026?
IOT jumped 24.0% (from $28.98 to $35.93) after analysts raised its forward EPS growth estimate to 27.6% on June 25.
The revision occurred amid strength in the technology sector, particularly in IoT and SaaS companies. Samsara's improving profitability outlook attracted buyers, and the upward estimate revision validated the positive trend. The screener detected this shift at $28.98, and the stock has since climbed to $35.93.
IOT EPS revision history → · Screener snapshot from 2026-06-25 →
FAQ: IOT
Why did IOT stock jump in late June 2026?
IOT rose 24.0% after analysts revised its next-year EPS growth estimate upward to 27.6% on June 25, driven by positive sector momentum and earnings optimism.
Is IOT a buy after the surge?
The 24% rally reflects the upgraded EPS estimate, but potential investors should assess whether the new estimate of 27.6% growth justifies the valuation.
What is IOT's EPS growth estimate?
Following the upward revision on June 25, 2026, IOT's forward EPS growth estimate is 27.6%.
Why did NMAX stock jump in July 2026?
NMAX jumped 20.0% (from $7.49 to $8.99) after analysts raised its forward EPS growth estimate from 159.1% to 376.9% on June 28.
The massive +217.8pp revision reflects a dramatic improvement in earnings expectations for Newsmax, likely tied to increased advertising or subscription revenue. While no specific news was announced, the estimate change alone was enough to drive a 20% gain in four trading days. Communication services sector tailwinds may have also contributed.
NMAX EPS revision history → · Screener snapshot from 2026-06-28 →
FAQ: NMAX
Why did NMAX stock jump in late June 2026?
NMAX soared 20% after analysts raised its forward EPS growth estimate from 159.1% to 376.9% on June 28, a 217.8 percentage point increase.
Is NMAX a buy after the rally?
The estimate revision was exceptionally large, but with no accompanying news, investors should verify the basis for such a dramatic upward revision before buying.
What is NMAX's EPS growth estimate?
As of June 28, 2026, NMAX's forward EPS growth estimate is 376.9%, up from 159.1%.
Why did HNGE stock jump in July 2026?
HNGE jumped 19.1% (from $70.56 to $84.05) after analysts raised its forward EPS growth estimate to 30.2% on June 24.
The revision came within the healthcare sector, specifically in digital health. Hinge Health's earnings outlook improved, likely reflecting better unit economics or user growth. The positive estimate change led to a sustained price increase over eight trading days.
HNGE EPS revision history → · Screener snapshot from 2026-06-24 →
FAQ: HNGE
Why did HNGE stock jump in late June 2026?
HNGE rose 19.1% after analysts revised its forward EPS growth estimate upward to 30.2% on June 24, signaling improving profitability.
Is HNGE a buy after the rally?
The 19.1% gain followed an upward EPS revision to 30.2% growth, but no company news was released; investors should examine the fundamentals supporting the new estimate.
What is HNGE's EPS growth estimate?
Following the revision on June 24, 2026, HNGE's forward EPS growth estimate stands at 30.2%.
Why did MRNA stock jump in July 2026?
MRNA jumped 18.6% (from $67.27 to $79.76) after analysts raised its forward EPS growth estimate to 45.4% on June 28.
Moderna's upward revision signals renewed confidence in its mRNA pipeline beyond COVID-19, possibly including RSV or cancer vaccines. The healthcare sector provided a supportive backdrop. Despite no specific earnings news, the significant EPS growth estimate of 45.4% attracted buyers, driving the 18.6% gain in four trading days.
MRNA EPS revision history → · Screener snapshot from 2026-06-28 →
FAQ: MRNA
Why did MRNA stock jump in late June 2026?
MRNA gained 18.6% after analysts raised its forward EPS growth estimate to 45.4% on June 28, reflecting optimism about its pipeline.
Is MRNA a buy after the rally?
The 18.6% jump was driven by an upward EPS revision to 45.4% growth, but investors should consider the lack of clinical or regulatory catalysts.
What is MRNA's EPS growth estimate?
As of June 28, 2026, MRNA's forward EPS growth estimate is 45.4%.
Today's top performers demonstrate the market's responsiveness to upward earnings estimate revisions, particularly in healthcare and technology sectors. The screening strategy of identifying early EPS revisions continues to capture significant price gains.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →